TY - JOUR
T1 - Disease Burden Estimates of Respiratory Syncytial Virus related Acute Respiratory Infections in Adults With Comorbidity
T2 - A Systematic Review and Meta-Analysis
AU - Shi, Ting
AU - Vennard, Sophie
AU - Jasiewicz, Francis
AU - Brogden, Rory
AU - Nair, Harish
AU - RESCEU Investigators
A2 - Fischer, Thea Kølsen
N1 - © The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: [email protected].
PY - 2022/8/12
Y1 - 2022/8/12
N2 - BACKGROUND: Respiratory syncytial virus related acute respiratory infection (RSV-ARI) constitutes a substantial disease burden in adults with comorbidities. We aimed to identify all studies investigating the disease burden of RSV-ARI in this group.METHODS: We estimated the incidence, hospitalization rate, and in-hospital case fatality ratio (hCFR) of RSV-ARI in adults with comorbidities based on a systematic review of studies published between January 1996 and March 2020. We also investigated the association between RSV-ARI and any comorbidity in adults. Meta-analyses based on random effects model were carried out.RESULTS: Overall, 20 studies were included. The annual incidence rate of RSV-ARI in adults with any comorbidity was 37.6 (95% confidence interval [CI], 20.1-70.3) per 1000 persons per year in industrialized countries and the seasonal incidence rate was 28.4 (11.4-70.9) per 1000 persons per season. The hCFR in industrialized countries was 11.7% (5.8%-23.4%). There were no studies in developing countries. There were insufficient data to generate the meta-estimate of hospitalization rate. The likelihood of experiencing RSV-ARI for those with any comorbidity compared to those without was estimated to be 4.1 (odds ratio [OR], 1.6-10.4) and 1.1 (OR, 0.6-1.8) from studies using univariable and multivariable analysis respectively.CONCLUSION: The disease burden of RSV-ARI among adults with comorbidity is substantial with limited data available.
AB - BACKGROUND: Respiratory syncytial virus related acute respiratory infection (RSV-ARI) constitutes a substantial disease burden in adults with comorbidities. We aimed to identify all studies investigating the disease burden of RSV-ARI in this group.METHODS: We estimated the incidence, hospitalization rate, and in-hospital case fatality ratio (hCFR) of RSV-ARI in adults with comorbidities based on a systematic review of studies published between January 1996 and March 2020. We also investigated the association between RSV-ARI and any comorbidity in adults. Meta-analyses based on random effects model were carried out.RESULTS: Overall, 20 studies were included. The annual incidence rate of RSV-ARI in adults with any comorbidity was 37.6 (95% confidence interval [CI], 20.1-70.3) per 1000 persons per year in industrialized countries and the seasonal incidence rate was 28.4 (11.4-70.9) per 1000 persons per season. The hCFR in industrialized countries was 11.7% (5.8%-23.4%). There were no studies in developing countries. There were insufficient data to generate the meta-estimate of hospitalization rate. The likelihood of experiencing RSV-ARI for those with any comorbidity compared to those without was estimated to be 4.1 (odds ratio [OR], 1.6-10.4) and 1.1 (OR, 0.6-1.8) from studies using univariable and multivariable analysis respectively.CONCLUSION: The disease burden of RSV-ARI among adults with comorbidity is substantial with limited data available.
KW - Adult
KW - Comorbidity
KW - Cost of Illness
KW - Hospitalization
KW - Humans
KW - Infant
KW - Respiratory Syncytial Virus Infections/epidemiology
KW - Respiratory Syncytial Virus, Human
KW - Respiratory Tract Infections/epidemiology
KW - adults
KW - acute respiratory infection
KW - comorbidity
KW - respiratory syncytial virus
UR - http://www.scopus.com/inward/record.url?scp=85136342697&partnerID=8YFLogxK
U2 - 10.1093/infdis/jiab040
DO - 10.1093/infdis/jiab040
M3 - Review
C2 - 34522961
SN - 0022-1899
VL - 226
SP - S17-S21
JO - The Journal of infectious diseases
JF - The Journal of infectious diseases
IS - Suppl 1
ER -